Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Chi Lin

Showing results (151-160 of 231) with videos related to

Pageof 24
Sort By:
Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
Ocular Immunology and Inflammation|October 29, 2019
Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' OrbitopathyShyang-Rong Shih, Shu-Lang Liao, Chih-Wei Shih, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2011
PR-104 plus sorafenib in patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Stephan L Chan, Chia-Chi Lin, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|October 20, 2017
Optimal usage of radium-223 in metastatic castration-resistant prostate cancerTai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Development (Cambridge, England)|February 1, 2008
Zebrafish cdx1b regulates expression of downstream factors of Nodal signaling during early endoderm formationPei-Yi Cheng, Chia-Chi Lin, Chun-Shiu Wu, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 4, 2018
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinomaTa-Chen Huang, Chia-Chi Lin, Yun-Chun Wu, et al.
Investigational New Drugs|March 3, 2019
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsJih-Hsiang Lee, Tom Wei-Wu Chen, Chih-Hung Hsu, et al.
Pageof 24

Showing results (151-160 of 231) with videos related to

Sort By:
Pageof 24
Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
Ocular Immunology and Inflammation|October 29, 2019
Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' OrbitopathyShyang-Rong Shih, Shu-Lang Liao, Chih-Wei Shih, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2011
PR-104 plus sorafenib in patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Stephan L Chan, Chia-Chi Lin, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|October 20, 2017
Optimal usage of radium-223 in metastatic castration-resistant prostate cancerTai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Development (Cambridge, England)|February 1, 2008
Zebrafish cdx1b regulates expression of downstream factors of Nodal signaling during early endoderm formationPei-Yi Cheng, Chia-Chi Lin, Chun-Shiu Wu, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 4, 2018
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinomaTa-Chen Huang, Chia-Chi Lin, Yun-Chun Wu, et al.
Investigational New Drugs|March 3, 2019
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsJih-Hsiang Lee, Tom Wei-Wu Chen, Chih-Hung Hsu, et al.
Pageof 24